Nasal airway and respiratory technology company Rhinomed (ASX:RNO) has announced the TGA has registered its high load capturing nasal swab as a Class 1 device.
The company said the new swab can collect samples from both nostrils simultaneously to test for the presence of upper respiratory tract diseases including influenza and COVID-19. The design enables the collection of a larger sample and creates the opportunity for mass high-frequency testing.
This novel nasal swab was recently registered in the US.
The company said it is now rapidly scoping out local and foreign manufacturing, assessing additive manufacturing (3D printing) solutions and advancing discussions with potential commercial partners.